Contact
searchSearch
HMP Global
Login

Leukemia & Lymphoma Excellence Forum Excellence Forum

Leukemia & Lymphoma Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Sarah Rutherford, MD
Videos
Approaches and Strategies for Treating Elderly Patients With Hodgkin Lymphoma
10/17/2025
Sarah C. Rutherford, MD
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Sarah Rutherford, MD, shares case presentations of elderly patients with Hodgkin lymphoma and the strategies she utilizes to treat these patients.
At the 2025 Lymphoma, Leukemia, & Myeloma Congress, Sarah Rutherford, MD, shares case presentations of elderly patients with Hodgkin lymphoma and the strategies she utilizes to treat these patients.
At the 2025 Lymphoma, Leukemia,...
10/17/2025
Oncology
Ibrahim Aldoss, MD
Conference Coverage
Ponatinib vs Imatinib for Patients Without MRD Negativity at End of Induction: Phase 3 PhALLCON Trial
06/01/2025
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD shares results from a post hoc analysis of the phase 3 PhALLCON study which showed clinical benefit with ponatinib vs imatinib for patients with ALL who did not achieve MRD negativity by end of induction.
Ibrahim Aldoss, MD shares results from a post hoc analysis of the phase 3 PhALLCON study which showed clinical benefit with ponatinib vs imatinib for patients with ALL who did not achieve MRD negativity by end of induction.
Ibrahim Aldoss, MD shares...
06/01/2025
Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
Peter Martin, MD
Conference Coverage
Novel Advancements in Marginal Zone Lymphoma Research
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Oncology
Mrinal Patnaik, MD
Conference Coverage
Exploring Diagnostic Criteria and Treatment Options for Patients With CMML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
Myron Czuczman, MD
Videos
Insights into the FDA Approval of Denileukin Diftitox for R/R Cutaneous T-Cell Lymphoma Treatment
08/27/2024
Myron Czuczman, MD, discusses Pivotal Study 302, which led to the FDA approval of denileukin diftitox for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma.
Myron Czuczman, MD, discusses Pivotal Study 302, which led to the FDA approval of denileukin diftitox for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma.
Myron Czuczman, MD, discusses...
08/27/2024
Oncology
Jakub Svoboda, MD
Conference Coverage
Examining Efficacy and Safety of Novel Armored huCART19-IL18 Treatment for Patients With R/R Lymphoma
06/13/2024

Featuring Jakub Svoboda, MD

Featuring Jakub Svoboda, MD ...
Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.
Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.
Jakub Svoboda, MD, discusses...
06/13/2024
Oncology
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA,...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Julie Vose, MD
Videos
Advances in Treatment Options for Patients With T-Cell Lymphoma
10/24/2023
Julie Vose, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia &...
10/24/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Predicting Long-Term Effects Among Patients Treated for Early-Stage Hodgkin Lymphoma
09/07/2023
Andrew M. Evens, DO, MSc
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates &...
09/07/2023
Oncology

What Your Colleagues Are Reading

Videos
Pediatric Pilocytic Astrocytoma With a KIAA1549:BRAF Fusion
05/20/2024
Shubin Shahab, MD, PhD, discusses how to treat a patient with pediatric pilocytic astrocytoma with a KIAA1549:BRAF fusion.
Shubin Shahab, MD, PhD, discusses how to treat a patient with pediatric pilocytic astrocytoma with a KIAA1549:BRAF fusion.
Shubin Shahab, MD, PhD,...
05/20/2024
Oncology
Conference Coverage
Full-Dose Pacritinib Demonstrates Efficacy Among Patients With Myelofibrosis and Both Thrombocytopenia and Anemia
06/02/2024

Amber Denham

Amber Denham
Among patients with myelofibrosis who have both thrombocytopenia and anemia, study findings show full-dose pacritinib demonstrates efficacy for spleen, symptom, and transfusion response.
Among patients with myelofibrosis who have both thrombocytopenia and anemia, study findings show full-dose pacritinib demonstrates efficacy for spleen, symptom, and transfusion response.
Among patients with...
06/02/2024
Oncology
Conference Coverage
Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Allison Casey
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES...
06/13/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
Michael Wang, MD
Videos
Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment
07/09/2024
Michael Wang, MD
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data...
07/09/2024
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use